A Case of Secondary Amyloidosis in a Patient with Ankylosing Spondylitis Refractory to TNF-α Inhibitor |
Min-Jin Lee1, Seung-Geun Lee1, Eun-Kyoung Park1, Sun-Mi Jang1, Sung-Min Baek1, Geun-Am Song1, Geun-Tae Kim2 |
1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea 2Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea |
종양괴사인자 억제제 불응 강직성 척추염 환자에서 발생한 아밀로이드증 |
이민진1, 이승근1, 박은경1, 장선미1, 백성민1, 송근암1, 김근태2 |
1부산대학교 의학전문대학원 내과학교실 2고신대학교 의과대학 내과학교실 |
Correspondence:
Seung-Geun Lee, Tel: +82-51-240-7580, Fax: +82-51-241-7581, Email: sglee@pnuh.co.kr |
Received: 26 October 2013 • Revised: 8 January 2014 • Accepted: 7 March 2014 |
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/licenses/bync/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
Abstract |
Secondary amyloidosis occurs in patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). The major therapeutic approach to secondary amyloidosis involves controlling the underlying inflammatory disease. Tumor necrosis factor-alpha (TNF-α) inhibitors have revolutionized the treatment of rheumatic diseases; in many cases dramatic clinical improvement of secondary amyloidosis due to AS has been observed in response to treatment with these agents. However, the development of secondary amyloidosis associated with AS refractory to treatment with TNF-α inhibitors has been infrequently reported. Here, we described a case of a 37-year-old male patient with longstanding AS who was diagnosed with secondary amyloidosis due to high disease activity despite treatment with etanercept, adalimumab and infliximab. |
Key Words:
Spondylitis, Ankylosing; Amyloidosis; Tumor necrosis factor-alpha |
주제어:
강직성 척추염; 이차성 아밀로이드증; 종양괴 사인자 억제제 |
|